Cardiac shockwave therapy leads to the regeneration of heart tissue after coronary bypass surgery, a study published in the prominent European Heart Journal showed.Read More
Stem and progenitor cell therapy is a novel approach to improve neovascularization and function of ischemic tissue. Enhanced tissue expression of chemoattractant factors such as stromal cell–derived factor 1 and vascular endothelial growth factor is crucial for the recruitment of circulating endothelial progenitor cells (EPCs) during acute ischemia. In chronic ischemia, however, expression of these...Read More
The cells are then injected back into the patient, to help repair damaged tissue. Original claims that they differentiated into replacement cells have been rejected , and many clinicians now believe that the cells act by releasing molecules that cause inflammation, with an attendant growth of oxygen-delivering small blood vessels, in the damaged tissue. Click...Read More
Enhancement of flap survival through extracorporeal shock wave treatment (ESWT) is a promising new technique; however, no attempt has been made to define the optimal time point and frequency of ESWT to optimize treatment with ESWT for ischemic indications. Click here to read more.Read More
Shock waves have been shown to induce recruitment of intravenously injected endothelial progenitor cells to ischemic hind limbs in rats. We hypothesized that shock wave treatment as sole therapy would induce angiogenesis in this ischemia model and would lead to mobilization of endogenous endothelial (progenitor) cells. Click here to read more.Read More
Ischemic heart disease represents a collective term for a continuous disease pathophysiology, ranging from acute myocardial infarction to congestive and chronic heart failure. According to the World Health Organization (WHO) and its Global Burden of Disease study 2010 ischemic heart disease represents the most common cause of death and disability-adjusted life years (DALY) worldwide. Click...Read More
Shock wave therapy (SWT) represents a clinically widely used angiogenic and thus regenerative approach for the treatment of ischaemic heart or limb disease. Despite promising results in preclinical and clinical trials, the exact mechanism of action remains unknown. Toll-like receptor 3, which is part of the innate immunity, is activated by binding doublestranded (ds) RNA....Read More
Tissue-engineered xenografts represent a promising treatment option in heart valve disease. However, inflammatory response leading to graft failure and incomplete in vitro repopulation with recipient cells remain challenging. Shock waves (SWs) were shown to modulate inflammation and to enhance re-epithelialization. We therefore aimed to investigate whether SWs could serve as a feasible adjunct to tissue...Read More
The main aim of our research in this field is to regenerate infarcted myocardium, respectively the hibernating myocardium. We use LAD ligation models – chronic, acute and ischemia/ reperfusion – in different species. Besides regeneration we work on the induction of angiogenesis as well as vasculogenesis. Click here to read more.Read More